William Blair Upgrades FibroGen to Outperform

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

byBenzinga Newsdesk

January 31, 2023

1 minute read

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

Marker Therapeutics Reports Received FDA Orphan Drug Designation For Multi-Antigen Targeted T Cell Therapy For Pancreatic Cancer

By Benzinga Newsdesk

Today, 7:33 AM

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and

MRKR

Here’s How Much $1000 Invested In Marsh & McLennan 15 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 7:33 AM

Marsh & McLennan (NYSE:MMC) has outperformed the market over the past 15 years by 6.8% on an annualized basis producing an average annual return of 12.8%. Currently, Marsh & McLennan has a market capitalization of $78.94 billion.

MMC

JonesTrading Upgrades Western Asset Mortgage to Buy

By Benzinga Newsdesk

Today, 7:33 AM

JonesTrading analyst Jason Stewart upgrades Western Asset Mortgage (NYSE:WMC) from Hold to Buy.

WMC

HUYA Earlier Reported Q3 EPS $0.12 Beats $0.04 Estimate, Sales $461.80M Miss $475.52M Estimate

By Bill Haddad

Today, 7:33 AM

HUYA (NYSE:HUYA) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.04 by 200 percent. This is a 45.45 percent decrease over earnings of $0.22 per share from the same period

HUYA

William Blair Upgrades FibroGen to Outperform

Related Posts

Marker Therapeutics Reports Received FDA Orphan Drug Designation For Multi-Antigen Targeted T Cell Therapy For Pancreatic Cancer

Here’s How Much $1000 Invested In Marsh & McLennan 15 Years Ago Would Be Worth Today

JonesTrading Upgrades Western Asset Mortgage to Buy

HUYA Earlier Reported Q3 EPS $0.12 Beats $0.04 Estimate, Sales $461.80M Miss $475.52M Estimate